This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ramos-Vara, J. A. Articles by Valli, V. E. O. Search for Related Content PubMed PubMed Citation Articles by Ramos-Vara, J. A. Articles by Valli, V. E. O.

Immunohistochemical Detection of Multiple Myeloma 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Plasmacytoma: Comparison with CD79a and CD20

Animal Disease Diagnostic Laboratory and Department of Comparative Pathobiology, School of Veterinary Medicine, Purdue University, West Lafayette, Indiana (JAR, MAM), Department of Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL (VEV)

Multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4) is involved in lymphoid cell differentiation, particularly in the production of plasma cells. We examined the immunoreactivity of mouse monoclonal antibody Mum-1p to MUM1/IRF4 and compared it with expression of CD79a and CD20 in 109 plasmacytomas in 107 dogs. Tissues had been fixed in formalin and embedded in paraffin. One hundred one of 109 (93.5%) tumors were positive for MUM1/IRF4. The staining was nuclear with weak cytoplasmic reaction. Fifty-nine of 105 (56.2%) plasmacytomas were positive for CD79a; only 21 of 108 (19.4%) cases were positive for CD20. MUM1/IRF4 staining was performed on 139 other tumors including B- and T-cell lymphomas, histiocytic proliferations, mast cell tumors, and melanocytic tumors. The only MUM1/IRF4-positive nonplasmacytic tumors were 10 B-cell lymphomas and 1 anaplastic lymphoma. We conclude the following: 1) Antibody Mum-1p is very specific for canine plasmacytomas, 2) antibody Mum-1p is superior in sensitivity and specificity to CD79a and CD20 for the identification of canine plasmacytomas in formalin-fixed, paraffin-embedded tissues, 3) canine lymphomas that express MUM1/IRF4 are few and usually of B-cell origin, 4) other canine leukocytic and melanocytic tumors do not express MUM1/IRF4, and 5) prospective studies are needed to determine whether the expression of MUM1/IRF4, particularly in lymphomas, has prognostic significance.

Key words: CD20; CD79a; dogs; immunohistochemistry; lymphoma; MUM1/IRF4; pathology; plasmacytoma.

Request reprints from Dr. J .A. Ramos-Vara, Animal Disease Diagnostic Laboratory, Purdue University, 406 South University, West Lafayette, IN 47907 (USA). E-mail: ramosja{at}purdue.edu

This article has been cited by other articles:

				J. A. Ramos-Vara, M. Kiupel, T. Baszler, L. Bliven, B. Brodersen, B. Chelack, S. Czub, F. D. Piero, S. Dial, E.J. Ehrhart, et al. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories J Vet Diagn Invest, July 1, 2008; 20(4): 393 - 413. [Abstract] [Full Text] [PDF]